Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers

FDA continues to emphasize the routine and the positive, even though strains on staff and sponsors increase as shutdown grinds on. CBER's new clinical reviewers would oversee the clinical investigation, development and review of cell and gene therapies, although a timeline on the hiring is unclear.

Decorin protein

In anticipating a glut of new investigational new drug (IND) applications for cell and gene therapies in the coming years, the US FDA announced its goal to add 50 additional clinical reviewers to deal with the growing workload.

In a Jan. 15 statement from FDA Commissioner Scott Gottlieb and Center for Biologics Evaluation and Research (CBER) Director Peter...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies